• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Self-assembled serum albumin-poly(L-lactic acid) nanoparticles: a novel nanoparticle platform for drug delivery in cancer
【24h】

Self-assembled serum albumin-poly(L-lactic acid) nanoparticles: a novel nanoparticle platform for drug delivery in cancer

机译：自组装血清白蛋白-聚（L-乳酸）纳米粒子：在癌症中药物输送的新型纳米粒子平台。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We developed a new self-assembled bovine serum albumin-poly(L-lactic acid) nanoparticle platform for anticancer drug delivery made from a bovine serum albumin-poly(L-lactic acid) polymer conjugate. Depending on the ratio of bovine serum albumin (BSA) to poly(L-lactic acid) (PLLA), these conjugates self-assemble into uniform spherical nanoparticles with different sizes. Then, BA-loaded BSA-PLLA nanoparticles (BSA-PLLA/BA NPs) were prepared by using BSA-PLLA conjugates as prototype materials, and betulinic acid (BA) as a model drug. In vitro cytotoxicity studies with human lung cancer cell lines (A549) and murine Lewis lung carcinoma (LLC) cell lines suggested that the BSA-PLLA/BA NPs were significantly superior to the model drug BA in antitumor activity and the BSA-PLLA NPs were non-toxic. Compared to free BA, the BSA-PLLA/BA NPs provided significantly higher blood circulation half-time of free BA (5.02-fold). The antitumor effect of the BSA-PLLA/BA NPs in a mouse tumor xenograft model showed much better tumor inhibition efficacy and fewer side effects than that of free BA. It may be attributed to the preferential tumor accumulation and increases the solubility of the drug in water, strongly supporting their use as high-performance carriers for anti-cancer therapy.
机译：我们开发了一种新的自组装牛血清白蛋白-聚（L-乳酸）纳米粒子平台，用于由牛血清白蛋白-聚（L-乳酸）聚合物共轭物制成的抗癌药物递送。根据牛血清白蛋白（BSA）与聚（L-乳酸）（PLLA）的比例，这些结合物会自组装成大小不同的均匀球形纳米颗粒。然后，以BSA-PLLA缀合物为原型材料，以桦木酸（BA）为模型药物，制备了BA负载的BSA-PLLA纳米颗粒（BSA-PLLA / BA NPs）。对人肺癌细胞系（A549）和鼠Lewis肺癌（LLC）细胞系的体外细胞毒性研究表明，BSA-PLLA / BA NPs在抗肿瘤活性方面显着优于模型药物BA，而BSA-PLLA NPs在抗肿瘤活性方面明显优于模型药物BA。无毒。与游离BA相比，BSA-PLLA / BA NP提供的游离BA的血液循环半衰期显着更高（5.02倍）。 BSA-PLLA / BA NPs在小鼠肿瘤异种移植模型中的抗肿瘤作用比游离BA表现出更好的肿瘤抑制功效和更少的副作用。这可能归因于肿瘤的优先积累，并增加了药物在水中的溶解度，有力地支持了它们作为抗癌治疗的高性能载体的用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号